Tipifarnib promising in advanced breast cancer

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1402, 2003-01, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tipifarnib, a farnesyl transferase inhibitor, appears to have potential for patients with locally advanced breast cancer

By  

Inpharma, Vol. 1, Iss. 1620, 2008-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Neoadjuvant trastuzumab promising in breast cancer

By  

Inpharma, Vol. 1, Iss. 1484, 2005-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Targeted therapy combos promising for breast cancer

By  

Inpharma, Vol. 1, Iss. 1640, 2008-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Adjuvant trastuzumab promising but costly for breast cancer

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 500, 2006-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Carbazole derivatives: a promising scenario for breast cancer treatment

By  

Mini Reviews in Medicinal Chemistry, Vol. 16, Iss. 8, 2016-05 ,pp. : 630-643

Bentham Science Publishers

Access to resources Recommend Favorite